Stimulant use and its impact on growth in children receiving growth hormone therapy: an analysis of the KIGS International Growth Database. 2014

Bradley S Miller, and Ferah Aydin, and Frida Lundgren, and Anders Lindberg, and Mitchell E Geffner
Pediatrics, University of Minnesota Amplatz Children's Hospital, Minneapolis, Minn., USA.

BACKGROUND Children receiving stimulants for attention deficit hyperactivity disorder (ADHD) frequently present to pediatric endocrinology clinics for evaluation and treatment of growth disorders. The worldwide prevalence of stimulant use in children with ADHD also receiving recombinant human growth hormone (rhGH) and the impact on response to rhGH are unknown. METHODS Data on children enrolled in the KIGSĀ® (Pfizer International Growth Study) registry were evaluated for the associated diagnosis of ADHD prior to initiation of GenotropinĀ® rhGH. Concomitant stimulant medications and auxological information were captured. Response to rhGH was evaluated using established growth prediction models. RESULTS The prevalence of ADHD in KIGS was 2.3% (1,748/75,251), with stimulants used in 1.8% (1,326/75,251). Children with idiopathic growth hormone deficiency (IGHD) who received stimulants grew significantly less (1.1 cm) in the first year of rhGH therapy than expected for rhGH-treated non-ADHD IGHD children. After one year of rhGH, idiopathic short stature (ISS) children with ADHD were significantly shorter [0.74 cm (with stimulants) and 0.69 cm (without stimulants)] than non-ADHD ISS children. CONCLUSIONS We demonstrated an impaired response to rhGH in IGHD and ISS children with ADHD. Our findings suggest that the ADHD phenotype, alone or in conjunction with stimulant therapy, may impair the short-term growth response to rhGH.

UI MeSH Term Description Entries
D008297 Male Males
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002657 Child Development The continuous sequential physiological and psychological maturing of an individual from birth up to but not including ADOLESCENCE. Infant Development,Development, Child,Development, Infant
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004393 Dwarfism, Pituitary A form of dwarfism caused by complete or partial GROWTH HORMONE deficiency, resulting from either the lack of GROWTH HORMONE-RELEASING FACTOR from the HYPOTHALAMUS or from the mutations in the growth hormone gene (GH1) in the PITUITARY GLAND. It is also known as Type I pituitary dwarfism. Human hypophysial dwarf is caused by a deficiency of HUMAN GROWTH HORMONE during development. Growth Hormone Deficiency Dwarfism,Hypophysial Dwarf,Hyposomatotrophic Dwarfism,Pituitary Dwarf,Dwarfism, Growth Hormone Deficiency,Isolated GH Deficiency,Isolated Growth Hormone Deficiency,Isolated HGH Deficiency,Isolated Human Growth Hormone Deficiency,Isolated Somatotropin Deficiency,Isolated Somatotropin Deficiency Disorder,Nanism, Pituitary,Pituitary Dwarfism,Pituitary Nanism
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000697 Central Nervous System Stimulants A loosely defined group of drugs that tend to increase behavioral alertness, agitation, or excitation. They work by a variety of mechanisms, but usually not by direct excitation of neurons. The many drugs that have such actions as side effects to their main therapeutic use are not included here. Analeptic,Analeptic Agent,Analeptic Drug,Analeptics,CNS Stimulant,CNS Stimulants,Central Nervous System Stimulant,Central Stimulant,Analeptic Agents,Analeptic Drugs,Central Stimulants,Agent, Analeptic,Agents, Analeptic,Drug, Analeptic,Drugs, Analeptic,Stimulant, CNS,Stimulant, Central,Stimulants, CNS,Stimulants, Central
D001289 Attention Deficit Disorder with Hyperactivity A behavior disorder originating in childhood in which the essential features are signs of developmentally inappropriate inattention, impulsivity, and hyperactivity. Although most individuals have symptoms of both inattention and hyperactivity-impulsivity, one or the other pattern may be predominant. The disorder is more frequent in males than females. Onset is in childhood. Symptoms often attenuate during late adolescence although a minority experience the full complement of symptoms into mid-adulthood. (From DSM-V) ADHD,Attention Deficit Disorder,Attention Deficit Hyperactivity Disorder,Brain Dysfunction, Minimal,Hyperkinetic Syndrome,Minimal Brain Dysfunction,ADDH,Attention Deficit Disorders with Hyperactivity,Attention Deficit Hyperactivity Disorders,Attention Deficit-Hyperactivity Disorder,Attention Deficit Disorders,Attention Deficit-Hyperactivity Disorders,Deficit Disorder, Attention,Deficit Disorders, Attention,Deficit-Hyperactivity Disorder, Attention,Deficit-Hyperactivity Disorders, Attention,Disorder, Attention Deficit,Disorder, Attention Deficit-Hyperactivity,Disorders, Attention Deficit,Disorders, Attention Deficit-Hyperactivity,Dysfunction, Minimal Brain,Syndromes, Hyperkinetic

Related Publications

Bradley S Miller, and Ferah Aydin, and Frida Lundgren, and Anders Lindberg, and Mitchell E Geffner
January 2009, Hormone research,
Bradley S Miller, and Ferah Aydin, and Frida Lundgren, and Anders Lindberg, and Mitchell E Geffner
January 2003, Journal of pediatric endocrinology & metabolism : JPEM,
Bradley S Miller, and Ferah Aydin, and Frida Lundgren, and Anders Lindberg, and Mitchell E Geffner
October 2005, Journal of pediatric endocrinology & metabolism : JPEM,
Bradley S Miller, and Ferah Aydin, and Frida Lundgren, and Anders Lindberg, and Mitchell E Geffner
October 2006, Acta paediatrica (Oslo, Norway : 1992),
Bradley S Miller, and Ferah Aydin, and Frida Lundgren, and Anders Lindberg, and Mitchell E Geffner
January 1994, Problemy endokrinologii,
Bradley S Miller, and Ferah Aydin, and Frida Lundgren, and Anders Lindberg, and Mitchell E Geffner
October 1996, Acta paediatrica (Oslo, Norway : 1992). Supplement,
Bradley S Miller, and Ferah Aydin, and Frida Lundgren, and Anders Lindberg, and Mitchell E Geffner
November 2004, The Journal of clinical endocrinology and metabolism,
Bradley S Miller, and Ferah Aydin, and Frida Lundgren, and Anders Lindberg, and Mitchell E Geffner
December 1994, Acta paediatrica (Oslo, Norway : 1992). Supplement,
Bradley S Miller, and Ferah Aydin, and Frida Lundgren, and Anders Lindberg, and Mitchell E Geffner
January 1998, Hormone research,
Bradley S Miller, and Ferah Aydin, and Frida Lundgren, and Anders Lindberg, and Mitchell E Geffner
August 2010, The Journal of pediatrics,
Copied contents to your clipboard!